NewAmsterdam Pharma (NAMS) Equity Average (2022 - 2026)

NewAmsterdam Pharma has disclosed Equity Average across 5 years of filings, most recently posting $674.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $674.3 million, down 12.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $674.3 million (down 12.13% YoY), and the FY2025 annual result was $720.5 million, up 37.77% from the prior year.
• Equity Average came in at $674.3 million for Q1 2026 at NewAmsterdam Pharma, down from $705.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $777.9 million in Q2 2025 to a low of $275.6 million in Q4 2022.
• The 5-year median for Equity Average is $423.0 million (2023), against an average of $510.7 million.
• Across the five-year window, Equity Average dropped 21.57% in 2024 and jumped 119.2% in 2025, its largest moves.
• NewAmsterdam Pharma's Equity Average stood at $275.6 million in 2022, then grew by 12.5% to $310.1 million in 2023, then surged by 83.22% to $568.2 million in 2024, then gained by 24.21% to $705.8 million in 2025, then declined by 4.45% to $674.3 million in 2026.
• The last three Equity Average figures came in at $674.3 million (Q1 2026), $705.8 million (Q4 2025), and $753.3 million (Q3 2025), per Business Quant data.